- Home
- NIM vs CGEN Comparison
NIM vs CGEN Comparison
Compare NIM & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIM
- CGEN
- Stock Information
- Founded
- NIM 1992
- CGEN 1993
- Country
- NIM United States
- CGEN Israel
- Employees
- NIM N/A
- CGEN N/A
- Industry
- NIM Trusts Except Educational Religious and Charitable
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NIM Finance
- CGEN Health Care
- Exchange
- NIM Nasdaq
- CGEN Nasdaq
- Market Cap
- NIM 115.4M
- CGEN 125.3M
- IPO Year
- NIM N/A
- CGEN 2000
- Fundamental
- Price
- NIM $9.30
- CGEN $1.38
- Analyst Decision
- NIM
- CGEN
- Analyst Count
- NIM 0
- CGEN 0
- Target Price
- NIM N/A
- CGEN N/A
- AVG Volume (30 Days)
- NIM 35.4K
- CGEN 238.1K
- Earning Date
- NIM 01-01-0001
- CGEN 11-11-2025
- Dividend Yield
- NIM 3.46%
- CGEN N/A
- EPS Growth
- NIM N/A
- CGEN N/A
- EPS
- NIM N/A
- CGEN N/A
- Revenue
- NIM N/A
- CGEN $22,144,000.00
- Revenue This Year
- NIM N/A
- CGEN N/A
- Revenue Next Year
- NIM N/A
- CGEN $208.08
- P/E Ratio
- NIM N/A
- CGEN N/A
- Revenue Growth
- NIM N/A
- CGEN N/A
- 52 Week Low
- NIM $8.28
- CGEN $1.13
- 52 Week High
- NIM $9.74
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- NIM 66.36
- CGEN 41.92
- Support Level
- NIM $9.21
- CGEN $1.32
- Resistance Level
- NIM $9.35
- CGEN $1.47
- Average True Range (ATR)
- NIM 0.07
- CGEN 0.06
- MACD
- NIM 0.01
- CGEN -0.00
- Stochastic Oscillator
- NIM 79.31
- CGEN 33.33
About NIM Nuveen Select Maturities Municipal Fund
Nuveen Select Maturities Municipal Fund is a diversified closed-end management investment company. Its primary investment objective is to provide current income exempt from regular federal income tax, consistent with the preservation of capital. Its secondary investment objective is to enhance portfolio value relative to the municipal bond market through investments in tax-exempt municipal obligations that are underrated or undervalued, or that represent municipal market sectors that are undervalued.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.